Stockscreener 앱 받기
5.29
5.17%
0.26
전일 마감가:
$5.03
열려 있는:
$5.08
하루 거래량:
36,295
Relative Volume:
0.11
시가총액:
$100.81M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+8.85%
1개월 성능:
-20.33%
6개월 성능:
-9.26%
1년 성능:
+0.00%
1일 변동 폭
$5.08
$5.45
1주일 범위
$4.70
$5.45
52주 변동 폭
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
650-249-2727
주소
628 MIDDLEFIELD ROAD, PALO ALTO
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
5.39 | 94.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.65 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.69 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.38 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-07-23 | 재개 | Piper Sandler | Neutral |
| 2025-05-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-08 | 개시 | William Blair | Outperform |
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics Appoints New CFO Matthew Gall - TipRanks
Kalaris Therapeutics appoints Matthew Gall as chief financial officer By Investing.com - Investing.com UK
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - The Manila Times
Kalaris (KLRS) names Matthew Gall CFO amid Phase 1b/2 nAMD study enrollment - Stock Titan
Will Kalaris Therapeutics Inc. outperform the marketPortfolio Return Summary & Real-Time Volume Analysis Alerts - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
What to expect from Kalaris Therapeutics Inc. in the next 30 daysWatch List & Real-Time Volume Trigger Notifications - newser.com
Tools to assess Kalaris Therapeutics Inc.’s risk profileQuarterly Growth Report & Real-Time Market Sentiment Reports - newser.com
Can trapped investors hope for a rebound in Kalaris Therapeutics Inc.July 2025 Levels & Reliable Momentum Entry Alerts - newser.com
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target - Investing.com
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Declines By 40.5% - MarketBeat
How resilient is Kalaris Therapeutics Inc. stock in market downturnsTrade Performance Summary & Safe Swing Trade Setups - newser.com
How Kalaris Therapeutics Inc. stock performs in rate cut cyclesWeekly Trend Report & Consistent Income Trade Ideas - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.Weekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Is Kalaris Therapeutics Inc. stock positioned for digital transformationWatch List & Fast Entry Momentum Alerts - newser.com
Analyzing Kalaris Therapeutics Inc. with risk reward ratio chartsJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Kalaris Therapeutics Inc. stock outlook for YEAR2025 Performance Recap & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-31 05:04:53 - newser.com
Identifying reversal signals in Kalaris Therapeutics Inc.Weekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Kalaris to Present at Stifel 2025 Annual Healthcare Conference - Investing News Network
Kalaris (Nasdaq: KLRS) to present at Stifel Healthcare Conference; CEO & CMO 3:20–3:50 ET - Stock Titan
Leading vs lagging indicators on Kalaris Therapeutics Inc. performance2025 AllTime Highs & Safe Capital Growth Tips - newser.com
Published on: 2025-10-30 01:28:32 - newser.com
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.03%
0.32%
자본화:
|
볼륨(24시간):